Converge Bio
Category: AI in Healthcare
A generative AI platform designed to model the 'language of biology' by training large-scale models on DNA, RNA, and protein sequences to accelerate and de-risk drug discovery. Converge Bio was founded in 2024. The company is led by Dov Gertz. Based in Tel Aviv, Israel. Team size: 10-50. Total funding raised: $30M total. Latest round: Series A ($25M, Jan 2026). Key investors include Bessemer Venture Partners, TLV Partners, Vintage Investment Partners, Saras Capital.
AMW Analysis
Converge Bio operates a generative AI platform that models DNA, RNA, and protein sequences to accelerate drug discovery. Founded in 2024 and based in Tel Aviv, the company has raised $31 million in total funding, including a $25 million Series A round in January 2026 led by Bessemer Venture Partners. The platform trains large-scale models on molecular data rather than text, aiming to replace trial-and-error laboratory processes with predictive digital design.
Recent news indicates the platform has completed 40 programs, achieving protein manufacturing yield improvements of 4 to 7 times and discovering antibodies with single-digit nanomolar binding affinities. The company reports a 4.5x increase in protein yield and single-nanomolar antibody binding. By integrating DNA and protein modeling into a single system, Converge Bio seeks to reduce the fragmentation that slows pharmaceutical R&D. The Series A funding is intended to scale the platform, which is backed by executives from Meta and OpenAI. The company’s trajectory points toward expanding its generative lab approach to minimize clinical risk through computational hypothesis generation.
AMW analysis, generated from 3 tracked news signals.
- Founded
- 2024
- Headquarters
- Tel Aviv, Israel
- Team size
- 10-50
- Total funding
- $30M total
Value proposition
Transitions drug discovery from a slow, trial-and-error laboratory process to a predictive digital design framework, significantly reducing the time and cost required to identify viable therapeutic candidates.
Products and solutions
ConvergeAB™ (Antibody Design & Screening), ConvergeGEO™ (Gene Expression / Bio Manufacturing Optimization), ConvergeCELL™ (Virtual Cell Simulation — Target & Biomarker Discovery), Biological Foundation Models (DNA, RNA, Proteins) with private fine-tuning
Unique value
Unlike traditional AI tools that focus on specific protein folding or classification, Converge Bio builds generative 'foundation models' that understand the underlying grammar of all biological sequences, allowing for the creation of entirely novel biological entities.
Target customer
Pharmaceutical companies, biotechnology startups, and academic research institutions involved in drug development and genomic medicine.
Industries served
Biotechnology, Pharmaceuticals, Genomics, Healthcare AI, Life Sciences
Technology advantage
Leverages a cross-disciplinary team with deep expertise in both LLM architecture and CRISPR technology; the platform can simulate biological outcomes at a scale and speed that physical labs cannot match.
How they differentiate
Converge Bio offers a unified generative AI platform that models the 'language of biology' across DNA, RNA, and proteins simultaneously. Unlike competitors that focus on specific protein folding or internal pipelines, Converge provides plug-and-play, explainable AI systems designed to integrate directly into existing pharmaceutical R&D workflows.
Main competitors
EvolutionaryScale, Generate Biomedicines, Recursion Pharmaceuticals
Key partnerships
Bessemer Venture Partners (Lead Investor), TLV Partners, The Garage (Early-stage venture lab), Strategic advisors and investors from Meta, OpenAI, and Wiz
Notable customers
Teva Pharmaceuticals, Compugen, BiomX
Major milestones
Raised $5.5M Seed round led by TLV Partners in Nov 2024, Secured $25M Series A led by Bessemer Venture Partners in Jan 2026, Established strategic partnerships with global pharma leaders like Teva Pharmaceuticals
Growth metrics
Grown to a ~40-person team; completed over 40 programs with more than a dozen pharmaceutical and biotech customers.
Market positioning
AI-as-a-Service (AIaaS) platform provider for the biotechnology and pharmaceutical industries.
Geographic focus
North America (Boston) and Middle East (Tel Aviv, Israel)
Patents and IP
CEO Dov Gertz holds a U.S. patent for a machine-learning method used to discover novel CRISPR systems (developed in collaboration with Nobel laureate Jennifer Doudna).
About Dov Gertz
Dov Gertz is the CEO and Co-Founder of Converge Bio. He previously served as an Entrepreneur In Residence at The Garage and held research and engineering roles at Google. He is a recognized expert in bioinformatics, having developed a machine-learning method for discovering novel CRISPR systems, which resulted in a U.S. patent and a publication co-authored with Nobel laureate Jennifer Doudna.
Latest news about Converge Bio
- Converge Bio secured $25 million in Series A funding led by Bessemer Venture Partners to scale its generative AI for drug discovery. By training models on molecular data rather than text, the platform
- Converge Bio raised 25 million dollars in Series A funding led by Bessemer, bringing its total financing to 30 million dollars. 🚀 The platform has completed 40 programs, achieving 4 to 7 times higher
- Converge Bio secured 25 million USD in Series A funding led by Bessemer Venture Partners to scale its generative AI platform for biological data. Backed by Meta and OpenAI executives, the startup has
More AI in Healthcare companies
Official website: https://converge-bio.com
